Latest Conference Articles

Patients with radiation-associated breast angiosarcoma may have an effective treatment option with the combination of oral paclitaxel with encequidar.

Alpelisib in combination with letrozole demonstrated sustained efficacy and no new safety signals as treatment of patients with PIK3CA-mutant HR–positive, HER2-negative advanced breast cancer who received prior treatment with the combination of a CDK4/6 inhibitor and fulvestrant.

Adjuvant treatment with pertuzumab demonstrated a trend for greater benefit in patients with early breast cancer with a HER2 single-activated pathway determined by molecular subtyping using BluePrint assay.

The cumulative incidence of central nervous system recurrences was improved, and fewer deaths were observed with adjuvant neratinib as treatment of patients with early-stage HER2-positive breast cancer after trastuzumab-based therapy compared with placebo at 8 years of follow-up.

Favorable outcomes after treatment with the HER2-directed lapatinib were indicated by early declines in circulating tumor cell counts in patients with metastatic breast cancer who initially had HER2-negative primary tumors but positive HER2 CTCs, suggesting this could serve as a clinical biomarker.

Sara M. Tolaney, MD, MPH, discusses where she sees the treatment landscape evolving in the future for the treatment of patients with hormone receptor-positive metastatic breast cancer.

The addition of trilaciclib prior to gemcitabine and carboplatin chemotherapy significantly improved overall survival in patients with previously treated metastatic triple-negative breast cancer.

Patients with HER2-positive metastatic breast cancer treated with fam-trastuzumab deruxtecan-nxki had continued to experience extended durable responses and overall survival rates, along with tolerable toxicity in the phase 2 DESTINY-Breast01 study for which data were presented during the 2020 San Antonio Breast Cancer Symposium.

In the phase 3 MONALEESA-7 trial, patients with hormone receptor–positive, HER2-negative breast cancer had a significant improvement in overall survival and chemotherapy delay when treated with ribociclib plus endocrine therapy compared with placebo.

No significant differences in recurrence were observed between treatment with tamoxifen or anastrozole in postmenopausal women with locally excised ductal carcinoma in situ.

The use of whole breast irradiation can be omitted in patients 65 years and older with pT1-2 tumors on local control at 10 years after breast-conserving surgery and adjuvant endocrine therapy in low risk, older patients.

Patients with Oncotype Dx low-risk recurrence scores were classifed with high accuracy by PreciseDx by using only hematoxylin and eosin stain images and limited clinical data.

In the phase 3 KX-ORAX-001 clinical trial, treatment with paclitaxel in combination with encequidar achieved a 26.5% reduction in the risk of death compared with paclitaxel by intravenous injection in patients with metastatic breast cancer.

A retrospective exploratory analysis of 3 trials of ribociclib in patients with hormone receptor–positive, HER2-negative advanced breast cancer confirmed the prognostic value of intrinsic tumor subtype for efficacy outcomes with CDK4/6 inhibition.

A higher risk of new chronic controlled substance use was observed among women who underwent both a mastectomy and reconstructive surgery, those who received a breast cancer diagnosis, received chemotherapy and were younger.

Serial circulating tumor cell enumeration in patients with metastatic breast cancer has been shown to strongly predict overall survival outcomes. The prediction is possible when CTC assessments are performed at a median of 29 days following treatment initiation.

Data from a 29-practice consortium shows that oncologists tend to under-recognize substantial symptoms among patients with breast cancer receiving radiotherapy after they have undergone a lumpectomy, according to a presentation during the 2020 San Antonio Breast Cancer Symposium. The data underscore a need for improvement in symptom detection.

Invasive disease-free survival was prolonged in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer treated with abemaciclib in combination with standard endocrine therapy in the phase 3 monarchE trial, according to a presentation at the 2020 San Antonio Breast Cancer Symposium.

Five-year invasive disease-free survival and overall survival were improved with the addition of chemotherapy to endocrine therapy as treatment of premenopausal, but not postmenopausal, women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer and a recurrence score between 0 and 25.

MEDI2228 demonstrated promising clinical efficacy as treatment of patients with relapsed/refractory multiple myeloma with triple-refractory disease experiencing maintained responses in a phase 1 study.

A phase 1 trial showed early signals of tolerability and efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma with TRPH-222 across dose levels.

An analysis from the MURANO trial showed that venetoclax in combination with rituximab led to a more than doubling of time to next treatment compared with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Treatment with higher doses of CPX-351 in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia was significantly associated with prolonged hematologic recovery times during induction cycles 1 and 2.

The combination of selinexor plus pomalidomide and low-dose dexamethasone led to favorable responses in a cohort of patients with heavily pretreated multiple myeloma, warranting further investigation of the regimen in a phase 3 trial.

In older patients with comorbid classical Hodgkin lymphoma who are deemed unfit for combination chemotherapy, treatment with the antibody dug conjugate brentuximab vedotin appeared tolerable and achieved high response rates that were durable in some patients, according to results from the phase 2 SGN35-015 study.

Robert Zeiser, MD, discusses the findings from the phase 3 REACH3 clinical trial of ruxolitinib as treatment of patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.

A study presented during the 2020 ASH Annual Meeting has suggested that certain driver mutations for myeloproliferative neoplasms can be traced back to when they were acquired as early as in utero.

A high objective response rate was observed in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with LOXO-305, according to results of the phase 1/2 BRUIN trial presented during the 2020 ASH Annual Meeting.

Treatment with asciminib led to an almost doubling of the major molecular response rate compared with bosutinib at 24 weeks in patients with chronic-phase chronic myeloid leukemia.

The combination of pevonedistat and azacitidine demonstrated encouraging efficacy and longer event-free survival compared with azacitidine alone in patients with higher-risk myelodysplastic syndromes.